tert-butyl 4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate | 263383-22-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate
• 英文别名: 4-(3-thiophen-2-yl-[1,2,4]oxadiazol-5-yl)-piperidine-1-carboxylic acid tert-butyl ester；4-[3-(2-thienyl)-1,2,4-oxadiazol-5-yl]-N-Boc piperidine；t-butyl ester of 4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylic acid；Tert-Butyl 4-(3-Thiophen-2-Yl-1,2,4-Oxadiazol-5-Yl)piperidine-1-Carboxylate
• CAS: 263383-22-8
• 化学式: C₁₆H₂₁N₃O₃S
• 分子量: 335.427
• InChiKey: METBQPRXNZHZMB-UHFFFAOYSA-N

物化性质

• 沸点：
  472.3±55.0 °C(Predicted)
• 密度：
  1.229±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  96.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate 在 盐酸 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 10.0h， 生成 4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)-piperidine-1-carboxylic acid(2,2,2-trifluoro-ethyl)-amide
  参考文献：
  名称：

  Ethionamide Boosters: Synthesis, Biological Activity, and Structure−Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors

  摘要：

  We report in this article an extensive structure activity relationships (SAR) study with 58 thiophen-2-yl-1,2,4-oxadiazoles as inhibitors of EthR, a transcriptional regulator controling ethionamide bioactivation in Mycobacterium tuberculosis. We explored the replacement of two key fragments of the starting lead BDM31343. We investigated the potency of all analogues to boost subactive doses of ethionamide on a phenotypic assay involving M. tuberculosis infected macrophages and then ascertained the mode of action of the most active compounds using a functional target-based surface plasmon resonance assay. This process revealed that introduction of 4,4,4-trifluorobutyryl chain instead of cyanoacetyl group was crucial for intracellular activity. Replacement of 1,4-piperidyl by (R)-1,3-pyrrolidyl scaffold did not enhance activity but led to improved pharmacokinetic properties. Furthermore, the crystal structures of ligand-EthR complexes were 6:Insistent with the observed SAR. In conclusion, we identified EthR inhibitors that boost antibacterial activity of ethionamide with nanomolar potency while improving solubility and metabolic stability.

  DOI：

  10.1021/jm200076a
• 作为产物：
  描述：

  2-氰基噻吩 在 fac-tris(2-phenylpyridinato-N,C2')iridium(III) 、 potassium 2,3,5,6-tetrafluoropyridine-4-thiolate 、 三氟化硼乙醚 、 羟胺 、 potassium hydrogencarbonate 、 三苯基膦 作用下， 以 甲醇 、 水 、 二甲基亚砜 为溶剂， 反应 73.25h， 生成 tert-butyl 4-(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  四氟吡啶基硫醇盐作为实现 1,2,4-恶二唑光氧化还原烷基化的工具

  摘要：

  描述了一种使用卤代烷作为自由基前体对 1,2,4-恶二唑进行自由基官能化的方法。反应效率由四氟吡啶基硫醇钾添加剂决定，该添加剂具有双重作用。首先，硫醇盐将卤代烷转化为更具反应性的氟化芳基硫醚，后者经历 C-S 键的光氧化还原活化。其次，硫醇盐通过将烷基自由基转化回硫化物来减少烷基自由基的非生产性损失。

  DOI：

  10.1002/adsc.202400075

文献信息

• COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF
  申请人：Deprez Benôit

  公开号：US20110136823A1

  公开（公告）日：2011-06-09

  The present invention relates to the use of compounds with a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, for the preparation of a medicament for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy, to pharmaceutical compositions comprising them in combination with an antibiotic that is activatable via the EthA pathway, to compounds having a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, to pharmaceutical compositions comprising them and to their use as medicaments, especially medicaments for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy.

  本发明涉及具有增强抗生素活性的化合物，这些抗生素通过EthA酶途径可激活，用于制备预防和/或治疗如结核病和麻风病等分枝杆菌感染的药物；涉及包含这些化合物与通过EthA途径可激活的抗生素组合的药物组合物；涉及具有增强通过EthA酶途径可激活抗生素活性的化合物；涉及包含这些化合物的药物组合物；以及涉及它们作为药物，特别是用于预防和/或治疗如结核病和麻风病等分枝杆菌感染的药物的使用。
• Discovery of highly potent triazoleantifungal agents with piperidine-oxadiazole side chains
  作者：Xiaomeng He、Yan Jiang、Yongqiang Zhang、Shanchao Wu、Guoqiang Dong、Na Liu、Yang Liu、Jianzhong Yao、Zhenyuan Miao、Yan Wang、Wannian Zhang、Chunquan Sheng

  DOI：10.1039/c4md00505h

  日期：——

  A series of novel triazole antifungal agents containing piperidine-oxadiazole side chains were designed and synthesized. Compound11bwas highly active againstCandida albicanswith a MIC value of 0.016 μg mL⁻¹.

  一系列含有哌啶-噁二唑侧链的新型三唑类抗真菌药物被设计并合成。化合物11b 对白念珠菌表现出高活性，最小抑菌浓度（MIC）值为0.016 μg/mL。
• GPCR Agonists
  申请人：Edward Stuart

  公开号：US20090325924A1

  公开（公告）日：2009-12-31

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

  化合物式(I)或其药学上可接受的盐是GPCR激动剂，可用于治疗肥胖症和糖尿病。
• REGULATED BIOCIRCUIT SYSTEMS
  申请人：Obsidian Therapeutics, Inc.

  公开号：US20190192691A1

  公开（公告）日：2019-06-27

  The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.
• IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS
  申请人：CAMP4 THERAPEUTICS CORPORATION

  公开号：US20210254056A1

  公开（公告）日：2021-08-19

  The present invention provides methods and compositions for the evaluation, alteration and/or optimization of gene signaling. Methods and systems are also provided which exploit the information generated in the identification of new targets and non-canonical signaling pathways.